<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">91083</article-id>
<article-id pub-id-type="doi">10.7554/eLife.91083</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91083.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biochemistry and Chemical Biology</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1323-5541</contrib-id>
<name>
<surname>Gilsbach</surname>
<given-names>Bernd K.</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3663-2889</contrib-id>
<name>
<surname>Ho</surname>
<given-names>Franz Y.</given-names>
</name>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Riebenbauer</surname>
<given-names>Benjamin</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0005-1579-6851</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Xiaojuan</given-names>
</name>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4442-3841</contrib-id>
<name>
<surname>Guaitoli</surname>
<given-names>Giambattista</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8174-6397</contrib-id>
<name>
<surname>Kortholt</surname>
<given-names>Arjan</given-names>
</name>
<xref ref-type="aff" rid="a2">b</xref>
<xref ref-type="aff" rid="a3">c</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6494-6944</contrib-id>
<name>
<surname>Gloeckner</surname>
<given-names>Christian Johannes</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a4">d</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>a</label><institution>German Center for Neurodegenerative diseases (DZNE)</institution>, Tübingen, <country>Germany</country></aff>
<aff id="a2"><label>b</label><institution>Department of Cell Biochemistry, University of Groningen</institution>, Groningen, <country>The Netherlands</country></aff>
<aff id="a3"><label>c</label><institution>YETEM-Innovative Technologies Application and Research Centre Suleyman Demirel University West Campus</institution>, Isparta, <country>Turkey</country></aff>
<aff id="a4"><label>d</label><institution>Core Facility for Medical Bioanalytics, Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen</institution>, Tübingen, <country>Germany</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Dötsch</surname>
<given-names>Volker</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Goethe University Frankfurt</institution>
</institution-wrap>
<city>Frankfurt am Main</city>
<country>Germany</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Dötsch</surname>
<given-names>Volker</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Goethe University Frankfurt</institution>
</institution-wrap>
<city>Frankfurt am Main</city>
<country>Germany</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence: Arjan Kortholt (<email>a.kortholt@rug.nl</email>), Christian Johannes Gloeckner (<email>johannes.gloeckner@dzne.de</email>)</corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-11-28">
<day>28</day>
<month>11</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP91083</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-08-07">
<day>07</day>
<month>08</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-07-31">
<day>31</day>
<month>07</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.07.31.549909"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Gilsbach et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Gilsbach et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-91083-v1.pdf"/>
<abstract>
<title>Abstract</title><p>The Parkinson’s Disease (PD)-linked protein Leucine Rich Repeat Kinase 2 (LRRK2) consists of seven domains, including a kinase and a Roc G domain. Despite the availability of several high-resolution structures, the dynamic regulation of its unique intramolecular domain stack is nevertheless still not well understood. By in-depth biochemical analysis, assessing the Michaelis-Menten kinetics of the Roc G domain, we have confirmed that LRRK2 has similar to other Roco protein family members a K<sub>M</sub> value of LRRK2 that lays within the range of the physiological GTP concentrations within the cell. Furthermore, the R1441G PD variant located within a mutational hotspot in the Roc domain showed an increased catalytic efficiency. The most common PD variant G2019S, located in the kinase domain showed an increased K<sub>M</sub> and reduced catalytic efficiency, suggesting a negative feedback mechanism from the kinase domain to the G-domain. Auto-phosphorylation of the G1+2 residue (T1343) in the Roc P-loop motif is critical for this phosphoregulation of both the K<sub>M</sub> as well as the k<sub>cat</sub> values of the Roc-catalyzed GTP hydrolysis, most likely by changing the monomer-dimer equilibrium. Together our data reveal a novel intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism. Interestingly, PD mutants differently change the kinetics of the GTPase cycle, which might in part explain the difference in penetrance of these mutations in PD patients.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>LRRK2</kwd>
<kwd>GTPase</kwd>
<kwd>kinase</kwd>
<kwd>G protein</kwd>
<kwd>Michaelis-Menten kinetics</kwd>
<kwd>PD</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>negative feedback loop</kwd>
</kwd-group>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Nonsynonymous sequence variants within the Leucine Rich Repeat Kinase 2 (LRRK2) are associated with familial forms of Parkinsońs disease (PD) and are phenotypically indistinguishable from idiopathic forms of PD (iPD) (<xref ref-type="bibr" rid="c41">Paisan-Ruiz et al., 2004</xref>; <xref ref-type="bibr" rid="c57">Zimprich et al., 2004</xref>). In addition to defined pathogenic as well as PD-risk coding variants, the LRRK2 locus also contributes to an increased risk of developing iPD more generally, as shown in GWAS studies (<xref ref-type="bibr" rid="c44">Simon-Sanchez et al., 2009</xref>). LRRK2 is a multi-domain protein, which belongs to the Roco protein family (<xref ref-type="bibr" rid="c36">Marin et al., 2008</xref>). Besides a core module, conserved among the Roco proteins, consisting of a Roc (<underline>R</underline>as <underline>o</underline>f <underline>c</underline>omplex proteins) G-domain and a COR (<underline>C</underline>-terminal <underline>o</underline>f <underline>R</underline>oc) dimerization domain, which is followed by a kinase domain, it contains four predicted solenoid domains. The three N-terminal solenoid domains consist of Armadillo repeats followed by an Ankyrin domain and the namesake leucine-rich repeats, while the C-terminus is formed by a seven-bladed WD40 domain (<xref ref-type="bibr" rid="c38">Mills et al., 2012</xref>). By similarity, these domains are involved in protein-protein interactions and, based on recent structural models and high-resolution structures, are likely to be involved in the intramolecular regulation of the protein, as well, e.g. by keeping the kinase domain in an auto-inhibited state (<xref ref-type="bibr" rid="c10">Deniston et al., 2020</xref>; <xref ref-type="bibr" rid="c17">Gloeckner and Porras, 2020</xref>; <xref ref-type="bibr" rid="c21">Guaitoli et al., 2016</xref>; <xref ref-type="bibr" rid="c48">Taylor et al., 2020</xref>). LRRK2 has been suggested to shuttle between monomeric cytosolic states and kinase-active oligomeric forms localized at the membrane (<xref ref-type="bibr" rid="c4">Berger et al., 2010</xref>; <xref ref-type="bibr" rid="c28">James et al., 2012</xref>). Membrane-bound LRRK2 has been demonstrated to phosphorylate a specific set of Rab proteins at a conserved threonine residue within their switch II motif, including Rab8a and Rab10 (<xref ref-type="bibr" rid="c18">Gomez et al., 2019</xref>; <xref ref-type="bibr" rid="c46">Steger et al., 2016</xref>). Furthermore, LRRK2 kinase activity has been demonstrated to be involved in endo-lysosomal pathways, thereby being a regulator of the innate immunity (<xref ref-type="bibr" rid="c1">Ahmadi Rastegar and Dzamko, 2020</xref>; <xref ref-type="bibr" rid="c8">Bonet-Ponce and Cookson, 2019</xref>; <xref ref-type="bibr" rid="c13">Erb and Moore, 2020</xref>). Despite these findings, the exact molecular mechanisms underlying LRRK2 activation and regulation are not well understood.</p>
<p>It is clear that the kinase activity of LRRK2 is dependent on the guanine nucleotide binding capacity of the Roc domain. However, the exact mechanism of G-nucleotide action remains to be determined, in particular if the nucleotide state of the Roc domain influences kinase activity (<xref ref-type="bibr" rid="c5">Biosa et al., 2013</xref>; <xref ref-type="bibr" rid="c26">Ito et al., 2007</xref>; <xref ref-type="bibr" rid="c50">Taymans et al., 2011</xref>).</p>
<p>Previous work on the conserved RocCOR module of a bacterial Roco protein has suggested that the nucleotide state of the Roc domain regulates dimerization (<xref ref-type="bibr" rid="c11">Deyaert et al., 2017</xref>), a process that can also be correlated to the activation of kinases by auto-phosphorylation (<xref ref-type="bibr" rid="c3">Beenstock et al., 2016</xref>). Like, MAPKKKs, such as Raf, LRRK2 has also been shown to auto-phosphorylate (<xref ref-type="bibr" rid="c16">Gloeckner et al., 2006</xref>). In addition, the Roc domain has been identified as a major target of LRRK2 auto-phosphorylation by phospho-proteomic analysis (<xref ref-type="bibr" rid="c15">Gloeckner et al., 2010</xref>; <xref ref-type="bibr" rid="c20">Greggio et al., 2009</xref>; <xref ref-type="bibr" rid="c53">Webber et al., 2011</xref>). Furthermore, there are indications that auto-phosphorylation of the Roc G-domain modifies GTP-binding activities (<xref ref-type="bibr" rid="c53">Webber et al., 2011</xref>) and that trans-phosphorylation by the kinase domain of the LRRK2 orthologue <italic>Dictyostelium</italic> Roco4 enhances GTPase activity (<xref ref-type="bibr" rid="c34">Liu et al., 2016</xref>). In this study, we analyzed Roc activity of LRRK2 and its PD mutants in depth and by combining systematic mutational analysis with the determination of the Michaelis-Menten kinetics. Based on this analysis, we identified an intramolecular negative feedback loop defined by LRRK2 auto-phosphorylation.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Impact of PD variants on LRRK2 GTPase activity</title>
<p>We and others have previously determined a full Michaelis-Menten kinetics for the GTPase hydrolysis mediated by Roco proteins as well as for wild-type LRRK2 (<xref ref-type="bibr" rid="c33">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="c52">Wauters et al., 2018</xref>). LRRK2 has kinetical parameters comparable to other Roco protein family members. Strikingly, the K<sub>M</sub> value of LRRK2 lies within the range of the physiological GTP concentrations (around 500 µM (<xref ref-type="bibr" rid="c51">Traut, 1994</xref>)) within the cell. Therefore, changes in global cellular or local GTP concentration might have a high impact on protein activity. For this reason, we here fully assessed the enzyme kinetics of disease-associated PD variants, in particular those with confirmed disease co-segregation. For this purpose, we selected three pathogenic variants, R1441G, localized within the Roc domain, the Y1699C variant in the COR-A domain as well as the kinase-domain variant G2019S. All three variants significantly increase the phosphorylation of the LRRK2 substrates Rab8a, Rab10 and Rab12 (<xref ref-type="bibr" rid="c29">Kalogeropulou et al., 2022</xref>). In addition to full-length LRRK2 expressed in HEK293T cells, we included a LRRK2 RocCOR domain construct expressed as an MBP fusion protein from <italic>E. coli</italic> in this study. Besides the wild-type, the variants R1441G and Y1699C have been successfully expressed and purified from <italic>E. coli</italic>. For full-length LRRK2, only the Roc-domain variant R1441G as well as the kinase-domain variant G2019S could be analyzed due to considerable low expression and stability of a full-length LRRK2 Y1699C construct in HEK293T cells. LRRK2 wt, R1441G as well as Y1699C MBP-RocCOR constructs showed similar kinetical parameters in the standard radiolabeling assay (charcoal assay), which determines the release of free inorganic phosphate (Pi) (<xref ref-type="bibr" rid="c31">Leupold et al., 1983</xref>). While slight differences were observed in the individual K<sub>M</sub> as well as k<sub>cat</sub> values, the catalytic efficiency determined by k<sub>cat</sub>/K<sub>M</sub> was identical (<xref rid="fig1" ref-type="fig">Fig. 1 A-D</xref>; <xref rid="tbls1" ref-type="table">Supplemental Table 1</xref>). For full-length LRRK2, we have chosen an HPLC-based assay to overcome limitations in the amount of protein necessary to determine a full Michaelis-Menten kinetics. This assay determines the production of GDP by chromatographic separation of the nucleotides (<xref ref-type="bibr" rid="c2">Ahmadian et al., 1997</xref>). To ensure that both assays result in comparable results, we compared GTP hydrolysis rates (k<sub>obs</sub>) of full-length wt LRRK2 in both assays at two different GTP concentrations. Both assays, the HPLC-based assay as well as the charcoal assay, resulted in overall comparable kinetics, ensuring that the results of both assays can be directly compared (<xref rid="fig1" ref-type="fig">Fig 1E-F</xref>; <xref rid="tbl1" ref-type="table">Table 1</xref>). For the wild-type full-length LRRK2 protein, we have determined a k<sub>cat</sub> of 0.36 ± 0.02 min<sup>−1</sup> and a K<sub>M</sub> of 554 ± 62 µM confirming our previously published data thus demonstrating the robustness of the used HPLC-based assay (<xref ref-type="bibr" rid="c52">Wauters et al., 2018</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><p>Determination of kinetical parameters for LRRK2 GTP hydrolysis of PD variants by the Charcoal Assay. (A) Michaelis-Menten kinetics for pathogenic variant within the RocCOR module. (B) comparison of K<sub>M</sub> values. (C) Comparison of k<sub>cat</sub> values. (D) catalytic efficiency (k<sub>cat</sub>/K<sub>M</sub>). (E)-(G) Determination of k<sub>obs</sub> values for full-length LRRK2 at 100µM (E) and 2000µM (F) GTP. (H) Domain structure of LRRK2 and the position of PD variants analyzed in this study.</p></caption>
<graphic xlink:href="549909v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title>HPLC-based full-length LRRK2 Michaelis-Menten kinetics</title></caption>
<graphic xlink:href="549909v1_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<p>Interestingly, full-length LRRK2 bearing the R1441G variant, showed a decreased Michaelis-Menten constant (K<sub>M</sub> = 271 ± 27 µM) while the k<sub>cat</sub> increased compared to the wt (<xref rid="fig2" ref-type="fig">Figure 2A</xref>) leading to an augmented catalytic efficiency of that variant. In contrast, full-length G2019S LRRK2 showed a significantly increased K<sub>M</sub> value of 867 ± 110 µM compared to a wt reference (554 ± 62 µM), while no significant change in the k<sub>cat</sub> parameter (k<sub>cat</sub> = 0.36 min<sup>−1</sup>) was observed (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). Together our data show that LRRK2 has a K<sub>M</sub> value that lies within the range of the physiological GTP concentrations and full-length G2019S LRRK2 showed a significantly increased K<sub>M</sub> value.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><p>Comparison of PD mutants in the HPLC-based GTPase assay for the LRRK2 full-length protein. (A) Michaelis-Menten kinetics for the R1441G Roc-domain variant compared to LRRK2 wt. (B) Michaelis-Menten kinetics for the G2019S kinase-domain variant compared to LRRK2 wt. (C) Michaelis-Menten kinetics for a kinase-dead variant compared to LRRK2 wt.</p></caption>
<graphic xlink:href="549909v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>Auto-phosphorylation regulates GTPase activity</title>
<p>Since the pathogenic G2019S variant has increased kinase activity, we next tested if a kinase-inactive variant has the opposite effect on GTPase activity. In fact, the K<sub>M</sub> value (K<sub>M</sub> = 181 ± 58 µM) for a K1906M kinase-dead LRRK2 variant is approximately three times lower compared to wt LRRK2 while the k<sub>cat</sub> value was only slightly reduced (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Consistently, MLi-2 treated fl. wt LRRK2 also has a lower K<sub>M</sub> value, which also ensures that the GTPase and not the kinase domain is the driver of the GTP consumption in our experimental set up (<xref ref-type="bibr" rid="c35">Liu and West, 2017</xref>). This strongly suggests a negative feedback signal on the Roc domain conferred by an active kinase conformation, most likely mediated via auto-phosphorylation. To further test this hypothesis, we incubated wild-type LRRK2 with ATP, <italic>in vitro</italic>. In fact, an incubation of the full-length wild-type protein with ATP for two hours at 30°C prior to determining its GTPase activity leads to altered Michaelis-Menten parameters, impacting the K<sub>M</sub> as well as k<sub>cat</sub> values. An approx. twofold increase in K<sub>M</sub> (1036 ± 168 µM) and an approx. twofold decrease in k<sub>cat</sub> (0.13 ± 0.01min<sup>−1</sup>) demonstrate a strong reduction in LRRK2 GTPase activity by enforced auto-phosphorylation (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). As a control condition, to rule-out inactivation of the LRRK2 protein by degradation during pre-incubation, we incubated a dead variant (K1906M) with ATP, the same way as the wild-type, resulting in no significant change in K<sub>M</sub> and k<sub>cat</sub> values. This shows that auto-phosphorylation indeed negatively regulates the GTPase activity of LRRK2.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><p>Kinetic parameters upon ATP incubation/ Identification of T1343 as relevant autophosphorylation site for a negative feedback loop. (A) Michaelis-Menten kinetics for LRRK2 wt +/− ATP, (B) Phospho-site screen: Position of the LRRK2 phosho-sites within the Roc domain which were included in the screen mapped on PDB:7LHW (<xref ref-type="bibr" rid="c40">Myasnikov et al., 2021</xref>). Individual domains are highlighted in color as follows: Armadillo (gray), Ankyrin (green), LRR (yellow), Roc (magenta), COR (wheat), Kinase (blue), WD40 (dark green). (C) Michaelis-Menten kinetics for T1343A LRRK2 +/− ATP.</p></caption>
<graphic xlink:href="549909v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c">
<title>The P-loop site T1343 is a critical site for LRRK2 phosphoregulation</title>
<p>To identify the phospho-sites that are important for the feedback mechanism, we tested several serine/ threonine to alanine mutants (<xref rid="fig3" ref-type="fig">Figure 3B</xref>), expecting that the critical auto-phosphorylation site would show no change in k<sub>cat</sub> and K<sub>M</sub> values upon <italic>in vitro</italic> ATP treatment. By mass-spectrometric mapping, we and others have previously demonstrated that the Roc domain is a hub for LRRK2 autophosphorylation (<xref ref-type="bibr" rid="c15">Gloeckner et al., 2010</xref>; <xref ref-type="bibr" rid="c20">Greggio et al., 2009</xref>; <xref ref-type="bibr" rid="c53">Webber et al., 2011</xref>).</p>
<p>All Roc autophosphorylation site mutants tested, with the exception of T1343A, showed wild-type behavior upon ATP treatment. In fact, T1343A showed no increase in K<sub>M</sub> values, suggesting this is the regulatory site that is crucial of the feedback mechanism (<xref rid="figs2" ref-type="fig">Supplemental Figure 2</xref>, <xref rid="fig3" ref-type="fig">Figure 3C</xref>). A detailed overview of the kinetical analysis of T1343A in comparison to pathogenic variants as well as kinase-dead LRRK2 is shown in <xref rid="fig4" ref-type="fig">Figure 4</xref>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><p>Overview of the kinetical parameters for fl. LRRK2 GTPase determined by the HPLC assay. (A) K<sub>M</sub> values. (B) k<sub>cat</sub> values and (C) catalytic efficiency (k<sub>cat</sub>/K<sub>M</sub>). Significant differences have been determined by an ANOVA followed by a post hoc test (p=0.05: *).</p></caption>
<graphic xlink:href="549909v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In a recent work we could demonstrate that LRRK2 dimerization is impacted by LRRK2 autophosphorylation (<xref ref-type="bibr" rid="c22">Guaitoli et al., 2023</xref>). In fact, autophosphorylation is shifting the monomer/dimer (m/d) equilibrium towards the monomeric form. Given the relevance for T1343 phosphorylation on LRRK2 GTPase activity and the fact that GTPase activity of Roco proteins is considered to be dependent on dimerization (<xref ref-type="bibr" rid="c11">Deyaert et al., 2017</xref>; <xref ref-type="bibr" rid="c19">Gotthardt et al., 2008</xref>), we wondered, if the observed negative-feedback might be mediated via a modulation of the m/d equilibrium. For this reason, we analyzed the relative abundance of monomers and dimers by mass photometry after ATP treatment for 30 min at 30°C (<xref ref-type="bibr" rid="c22">Guaitoli et al., 2023</xref>; <xref ref-type="bibr" rid="c42">Pathak et al., 2023</xref>). In contrast to the wild-type, which the m/d equilibrium could be shifted towards the monomer, this effect was abolished for T1343A (<xref rid="fig5" ref-type="fig">Figure 5</xref>). This suggests that the underlying mechanism of the negative-feedback phosphorylation towards lower GTPase activity might be mediated by an increased monomerization of LRRK2.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption><p>Autophosphorylation-induced LRRK2 monomerization as shown in <xref ref-type="bibr" rid="c22">Guaitoli et al., 2023</xref> (<xref ref-type="bibr" rid="c22">Guaitoli et al., 2023</xref>) is abolished by the T1343A variant. (A) Mass photometry assays for LRRK2 wt and (B) T1343A LRRK2. Significance has been determined by a student’s T-test (p=0.05: *; p=0.01: **).</p></caption>
<graphic xlink:href="549909v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>The phospho-null mutant T1343A is sufficient to disrupt the negative feedback in the LRRK2 signaling cascade in cells</title>
<p>Having identified an intramolecular negative-feedback on LRRK2-mediated GTP hydrolysis mediated by auto-phosphorylation, we were next interested to investigate its relevance in a cellular context. First, we analyzed the kinase activity of T1343A using an <italic>in vitro</italic> LRRKtide assay (<xref ref-type="bibr" rid="c27">Jaleel et al., 2007</xref>) to rule out that the unchanged K<sub>M</sub> and k<sub>cat</sub> values observed upon ATP treatment in our GTPase activity assays, are the result of kinase-inactive protein. For this purpose, we compared the kinase activities for LRRK2 T1343A with the wild-type protein, as well as the hyperactive G2019S variant and a kinase-dead control. By this assay, we could clearly demonstrate that T1343A confers specific kinase activity at a level comparable to the LRRK2 wt, while G2019S was clearly more active (<xref rid="fig6" ref-type="fig">Figure 6A</xref>). Next, we performed cell-based assays, comparing the phosphorylation levels of the LRRK2 substrate Rab10. To this end, we quantified established markers (pRab10 and pS935) for LRRK2 activity by Western blot analysis (<xref ref-type="bibr" rid="c29">Kalogeropulou et al., 2022</xref>) (<xref rid="fig6" ref-type="fig">Figure 6B</xref>). In agreement with published data (<xref ref-type="bibr" rid="c29">Kalogeropulou et al., 2022</xref>), the other PD mutations R1441G and I2020T showed an approx. 8-fold increase in Rab10 phosphorylation (<xref rid="fig6" ref-type="fig">Figure 6 C-D</xref>). Interestingly, the T1343A variant showed an approximately twofold increase in activity which is comparable with G2019S, while the double mutant T1343A/G2019S did not further increase Rab10 phosphorylation (and <xref rid="tbls3" ref-type="table">Supplemental Table 3</xref>). Together our results suggest that T1343 is crucial for the negative feedback in the LRRK2 signaling cascade in cells and the mutation to alanine disrupts this regulation. Therefore, the T1343A variant has a similar activity compared to G2019S and the double mutant T1343A/G2019S has no further increased activity.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><p>Effect of Roc T1343A on LRRK2 kinase activity and comparison to PD variants (A) <italic>In vitro</italic> LRRKtide HPLC-based kinase assay. (B) Western blot for LRRK2 pS935, total LRRK2, Rab10 pT73 and total Rab10. (C) Relative Rab phosphorylation levels. (D) Relative LRRK2 pS935 levels. Significant differences have been determined by an ANOVA followed by a post hoc test (p=0.05: *).</p></caption>
<graphic xlink:href="549909v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Although functional work on LRRK2 has been made significant progress in the past two decades, including the availability of high-resolution structures covering almost the entire protein in different conformations, the exact molecular mechanisms underlying LRRK2 activation and regulation have yet to be determined (<xref ref-type="bibr" rid="c49">Taymans et al., 2023</xref>). One entry point into these mechanisms is based on conserved mechanisms in kinase-associated cellular signaling. Kinases and G proteins are often found within the same signaling cascade, but with the exception of Roco-proteins, never on the same protein. On a contrary, the usual scheme of signaling is from the G protein via a kinase cascade towards gene expression is often regulated by the formation of signaling modules orchestrated by scaffolding proteins as given in the well-studied MAP-kinase signaling networks (<xref ref-type="bibr" rid="c6">Birtwistle and Kolch, 2011</xref>; <xref ref-type="bibr" rid="c30">Kolch, 2000</xref>). In addition, these pathways often include a negative feedback loop allowing a stable signal, a context-specific fine-tuning as well as shut-down of the system (<xref ref-type="bibr" rid="c6">Birtwistle and Kolch, 2011</xref>). For example, an EphA2-mediated negative feedback inhibition of the Ras–PI3K–AKT module leads to a cell cycle arrest (<xref ref-type="bibr" rid="c37">Menges and McCance, 2008</xref>).</p>
<p>Given that LRRK2 combines a G domain with a kinase domain, resembling canonical signaling modules, besides the investigation of the kinase activity (<xref ref-type="bibr" rid="c48">Taylor et al., 2020</xref>), quite some attention has been laid on the analysis of the GTPase activity (<xref ref-type="bibr" rid="c5">Biosa et al., 2013</xref>; <xref ref-type="bibr" rid="c25">Ho et al., 2016</xref>; <xref ref-type="bibr" rid="c32">Lewis et al., 2007</xref>; <xref ref-type="bibr" rid="c33">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="c34">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="c53">Webber et al., 2011</xref>; <xref ref-type="bibr" rid="c55">Wu et al., 2019</xref>). Nevertheless, knowledge of the exact interplay between these two domains is still limited. In addition, observations by most of the studies are based on single k<sub>obs</sub> values at considerable low GTP concentrations around or below the K<sub>M</sub> for full-length LRRK2-mediated GTP hydrolysis and/ or worked with truncated LRRK2 constructs (<xref ref-type="bibr" rid="c33">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="c52">Wauters et al., 2018</xref>). In this study, we have elucidated a negative feedback loop from kinase to GTPase, increasing the K<sub>M</sub> value of the Roc domain via autophosphorylation. Given an average physiological GTP concentration of approx. 500 µM within cells (<xref ref-type="bibr" rid="c51">Traut, 1994</xref>), the physiological impact of the differences in the K<sub>M</sub> values reported in this study, in combination with a negative feedback loop, leads to a strong perturbation of the tightly regulated LRRK2 activity. We could observe large changes in the K<sub>M</sub> induced by auto-phosphorylation, which supports our idea of an intramolecular negative-feedback. This feedback loop has an inhibitory effect on LRRK2 Roc-mediated GTP hydrolysis. Furthermore, our study revealed that different PD variants not only alter kinase but also change the kinetics of the Roc-mediated GTP hydrolysis. In fact, when looking at the catalytic efficiency it is striking that we found it to be increased for the R1441G variant located within a mutational hotspot of the Roc domain, also containing the PD variants R1441C, H and S, which is in good agreement with the penetrance of these variants (<xref ref-type="bibr" rid="c23">Haugarvoll et al., 2008</xref>). In contrast, the most prevalent LRRK2 PD variant G2019S shows an increase in K<sub>M</sub>, while the catalytic efficiency remained to be unchanged. This finding is also in well agreement with the different impact of these pathogenic variants on the Rab phosphorylation. While R1441G shows a strong Rab phosphorylation in cells, the effect mediated by G2019S is considerably weaker (<xref ref-type="bibr" rid="c29">Kalogeropulou et al., 2022</xref>). Furthermore, we could demonstrate that LRRK2 kinase activity is negatively regulating the Roc-mediated GTP hydrolysis.</p>
<p>By a systematic mutational analysis, removing confirmed phospho-sites within the Roc domain, we identified with T1343 a critical residue, involved in the auto-phosphorylation mediated negative feedback, in contrast to LRRK2 wt it also showed no difference in dimer-monomer formation upon ATP treatment. T1343 has initially been mapped by phosphoproteomic studies (<xref ref-type="bibr" rid="c15">Gloeckner et al., 2010</xref>; <xref ref-type="bibr" rid="c20">Greggio et al., 2009</xref>). Furthermore, it has been shown to be quantitatively phosphorylated in the C-terminal four-domain ‘RCKW’ construct allowing resolving the phospho-threonine in the recently published cryo-EM structure (<xref ref-type="bibr" rid="c10">Deniston et al., 2020</xref>). T1343A and T1343G variants have already been tested in two previous studies, however only at basal conditions and/or <italic>in vitro</italic> where similar activity was observed in comparison to wild-type LRRK2 (<xref ref-type="bibr" rid="c5">Biosa et al., 2013</xref>; <xref ref-type="bibr" rid="c47">Stormer et al., 2023</xref>). In agreement with our data, no effect of T1343G on <italic>in vitro</italic> kinase activity was observed (<xref ref-type="bibr" rid="c47">Stormer et al., 2023</xref>). Furthermore, replacing T1343 by a non-phosphorylatable residue reduced P<sup>33</sup> incorporation in phosphorylation assays by 50% (<xref ref-type="bibr" rid="c20">Greggio et al., 2009</xref>). Interestingly, according to phosphoproteomes curated in the PhosphoSitePlus database (<ext-link ext-link-type="uri" xlink:href="http://www.phoshposite.org">www.phoshposite.org</ext-link>) also other Rabs are phosphorylated either at a conserved serine or threonine residue at the homologous position (G1+2) within the P-loop (for a P-loop alignment of all Rabs see: (<xref ref-type="bibr" rid="c39">Mishra et al., 2013</xref>)), including Rab1a, Rab5a, Rab7a, Rab8a, Rab10, Rab13, Rab15, Rab17 and Rab35 as well as Rab2 and Rab22a, respectively. In addition, also Rab4, Rab34 are phosphorylated at a P-loop residue. Furthermore, the atypical Rab protein Rab24, has a phosphorylatable Tyrosine (Y17) at this position (<xref ref-type="bibr" rid="c12">Ding et al., 2003</xref>). In agreement with the findings for LRRK2 described here, Rab24 Y17A shows an increase intrinsic GTP hydrolysis rate (<xref ref-type="bibr" rid="c56">Wu et al., 2006</xref>). Together, these findings suggest, that P-loop phosphorylation is a relevant and conserved regulatory mechanism for Rab proteins.</p>
<p>What might be the biological consequence of this mechanism? As shown for its bacterial orthologue (<xref ref-type="bibr" rid="c11">Deyaert et al., 2017</xref>), increasing the GTP-loaded portion of LRRK2 favor its monomeric state. GTP hydrolysis leads, at least transiently, to a GDP-bound state of LRRK2, potentially inducing dimerization at a critical local protein concentration. LRRK2 kinase activity might counteract this mechanism by auto-phosphorylation of the P-loop residue T1343, shifting the equilibrium back to the monomeric state. Removing of this regulatory phosphosite leads to an LRRK2 activity comparable to G2019S, and cannot be further increased by introducing the double mutant T1343A/G2019S. This suggests that there is a tight regulation between GTPase activity, phosphorylation and monomer dimer equilibrium which all interplay with each other to regulate the LRRK2 signal output. Consistently, compounds target either the kinase, G-domain or dimerization can block LRRK2 activity and signaling (<xref ref-type="bibr" rid="c24">Helton et al., 2021</xref>; <xref ref-type="bibr" rid="c42">Pathak et al., 2023</xref>; <xref ref-type="bibr" rid="c54">Wojewska and Kortholt, 2021</xref>).</p>
<p>However, to fully understand the LRRK2 mechanism and further explore allosteric targeting of LRRK2, a better understanding of the complex and dynamic conformational changes underlying the local orchestration and activation of LRRK2 is necessary.</p>
<p>In conclusion, our study describes a novel intramolecular feedback mechanism of LRRK2, which is based on auto-phosphorylation. Similar to MAPK pathways where negative feedback mechanisms are essential to guarantee a robust signal, and also allowing a tight and context-specific shutdown of the pathway, the kinase domain in its active conformation negatively regulates GTP hydrolysis.</p>
</sec>
<sec id="s4">
<title>Material and Methods</title>
<sec id="s4a">
<title>DNA Constructs</title>
<p>Cloning of the LRRK2 cDNA from human lymphoblasts has been described in <xref ref-type="bibr" rid="c16">Gloeckner et al., 2006</xref> (<xref ref-type="bibr" rid="c16">Gloeckner et al., 2006</xref>). The LRRK2 cDNA was cloned into pDONR202 vector and further subcloned by the Gateway<sup>(TM)</sup> LR-reaction (Invitrogen) into the pDEST-NSF-TAP vector for the expression of an N-terminal FLAG/ tandem-STREP tag II tagged fusion protein (<xref ref-type="bibr" rid="c14">Gloeckner et al., 2007</xref>). Variants were introduced into the ENTRY construct by site-directed mutagenesis using the QuikChange<sup>(TM)</sup> II XL kit (Agilent). For the expression of the RocCOR construct in bacteria, a cDNA sequence corresponding to the LRRK2 amino acids 1293-1840 was subcloned into the pDEST-566 vector (N-terminal 6xHIS-MBP tag) using the Gateway<sup>(TM)</sup> system. pDEST-566 was a gift from Dominic Esposito (Addgene plasmid #11517; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:11517">http://n2t.net/addgene:11517</ext-link>; RRID: Addgene_11517).</p>
</sec>
<sec id="s4b">
<title>Purification of full-length LRRK2 from HEK293T cells</title>
<p>The purification of NSF-tagged full-length LRRK2 has been performed as described previously with minor adaptations (<xref ref-type="bibr" rid="c21">Guaitoli et al., 2016</xref>). Briefly, HEK293T cells (CRL-11268; American Type Culture Collection) were transfected between 50% and 70% confluence with 8 µg of plasmid DNA/ 14 cm culture dish using polyethyleneimine (PEI) 25 kDa (Polysciences), and cultured post-transfection for 48 hrs in 14 cm dishes in DMEM (Sigma-Aldrich) supplemented with 10% (vol/vol) FBS (Sigma-Aldrich) and appropriate antibiotics. After removal of the medium, the cells were resuspended in lysis buffer (1 mL / 14 cm dish) containing 30 mM Tris (pH 8.0), 150 mM NaCl, 5mM MgCl<sub>2</sub>, 3 mM DTE, 5% Glycerol and supplemented with 0.5 % (v/v) Nonidet P-40 substitute, complete protease inhibitor (Roche) and 0.1 mM GDP. Cell lysis was allowed to proceed for 1 h at 4°C on a rotating shaker (10 rpm) and cell debris and nuclei were removed by centrifugation at 10,000 × g for 10 min. The lysate was incubated with Strep-Tactin beads (IBA, 500 µl bed volume / 15 mL cell lysate) for 2 h at 4°C on a rotating shaker. The beads were transferred to a microspin column (GE healthcare) and washed extensively 5 times with washing buffer (30 mM Tris (pH 8.0), 150 mM NaCl, 3 mM DTT, 5 mM MgCl<sub>2</sub>, 5 % [vol/vol] glycerol) containing 0.1 mM GDP. Elution was performed with 500 µL of the same washing buffer containing 2.5 mM of D-Desthiobiotin (IBA) and 0.1 mM GDP. Purified proteins were further concentrated using ultracell-30 centrifugal filter units (30 kDa cutoff, Amicon) to reduce relative GDP amounts.</p>
</sec>
<sec id="s4c">
<title>Purification of 6xHIS-MBP-RocCOR from E. coli</title>
<p>6xHIS-MBP-RocCOR was purified according to standard protocols with minor adaptations (<xref ref-type="bibr" rid="c43">Riggs, 2001</xref>). Briefly, the RocCOR pDEST-566 vector was transformed in the E. coli BL21(DE3) strain. An overnight culture was used to inoculate into 2 L LB medium and grow at 37°C. When the culture reached an OD at 600 nm of about 0.7, protein expression was induced with 0.6 mM IPTG for 4 h at 20°C. Cells were harvested and resuspended in resuspension buffer (50 mM HEPES pH 8, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 % Glycerol, 0.5 mM GDP and 5 mM β-mercaptoethanol, supplemented with 1 mM PMSF and 1x cOmplete™ EDTA-free protease inhibitor cocktail (Roche)), and then lysed by sonication. The cell lysate was clarified by centrifugation at 70,000 x g, 4°C for 1 hr. The cleared cell lysate was loaded on a 5 mL MBPTrap column (GE Healthcare). The captured proteins were washed with 5 CV wash buffer (20 mM HEPES pH 8, 200 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 % Glycerol, 0.5 mM GDP and 5 mM β-mercaptoethanol), then 10 CV wash buffer supplemented with 5 mM ATP, and finally again with 5 CV wash buffer. The MBP fused protein was eluted in wash buffer containing 10 mM maltose.</p>
</sec>
<sec id="s4d">
<title>HPLC-based GTP hydrolysis assay</title>
<p>Steady-state kinetic measurements of LRRK2-mediated GTP hydrolysis were performed as previously described (<xref ref-type="bibr" rid="c2">Ahmadian et al., 1997</xref>). Briefly, 0.1 µM of full-length LRRK2 was incubated with different amounts of GTP (0, 25, 75, 150, 250, 500, 1000, 2000, 3000 and 5000 µM) and production of GDP was monitored by reversed phase C18 HPLC. To this end, the samples (10 µl) were directly injected on a reversed-phase C18 column (pre-column: Hypersil Gold, 3µm particle size, 4.6×10mm; main column: Hypersil Gold, 5µm particle size, 4.6×250mm, Thermo Scientific) using an Ultimate 3000 HPLC system (Thermo Scientific, Waltham, MA, USA) in HPLC-buffer containing 50 mM KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> pH 6.0, 10 mM tetrabutylammonium bromide and 10-15% acetonitrile. Subsequently, samples were analyzed using the HPLC integrator (Chromeleon 7.2, Thermo Scientific, Waltham, MA, USA). Initial rates of GDP production were plotted against the GTP concentration using GraFit5 (v.5.0.13, Erithacus Software). The number of experiments is indicated in the graph and data point is the average (±s.e.m.) of indicated repetitions. The Michaelis-Menten equation was fitted to determine K<sub>M</sub> (±s.e.) and k<sub>cat</sub> (±s.e.).</p>
</sec>
<sec id="s4e">
<title>HPLC-based LRRKtide assay</title>
<p>LRRK2, LRRKtide and ATP were mixed on ice to a final concentration 0.1 µM LRRK2, 200 µM LRRKtide and 1 mM ATP, in 30 mM Tris/HCl pH 8.0, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 5 mM DTE, 5% Glycerol, 0.1 mM GDP. Samples were taken at 0, 5, 10, 25, 45, 65, 90 and 120min. To stop the reaction TFA was added to a final concentration of 0.1% and the samples were kept on ice before HPLC analysis. To separate phospho from non-phospho LRRKtide the following HPLC protocol was used: Hypersil Gold C18 (2.1×150mm; 3 µm particle size,Thermo Scientific), Buffer A: 5% ACN, 0.1 % TFA, Buffer B: 80% ACN, 0.1% TFA, flow rate at 0.5 ml/min, detection at 202nm. The Elution profile was as follows: 0-1 min 100% Buffer A, 1-15 min Gradient up to 60% Buffer B, 15-17 min 100% Buffer B, 17-22 min 100% Buffer A. Subsequently, samples were analyzed using the HPLC integrator (Chromeleon 7.2, Thermo Scientific, Waltham, MA, USA). Rates of phospho-LRRKtide production were plotted against the time using GraFit5 (v.5.0.13, Erithacus Software).</p>
</sec>
<sec id="s4f">
<title>Charcoal GTP hydrolysis assay</title>
<p>The [γ-32P]GTP charcoal assay was performed as previously described (<xref ref-type="bibr" rid="c7">Bollag and McCormick, 1995</xref>). Briefly, 0.1 µM full-length LRRK2 or 0.5 µM 6xHIS-MBP-RocCOR was incubated with different GTP concentrations, ranging from 75 µM to 8 mM, in the presence of [γ-<sup>32</sup>P] GTP in GTPase assay buffer (30 mM Tris pH 8, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 5% (v/v) Glycerol and 3 mM DTT). Samples were taken at different time-points and immediately quenched with 5% activated charcoal in 20 mM phosphoric acid. All non-hydrolyzed GTP and proteins were stripped by the activated charcoal and sedimented by centrifugation. The radioactivity of the isolated inorganic phosphates was then measured by scintillation counting. The initial rates of γ-phosphate release and the Michaelis-Menten kinetics were calculated as described above.</p>
</sec>
<sec id="s4g">
<title>Mass photometry</title>
<p>MP was performed as described in (<xref ref-type="bibr" rid="c22">Guaitoli et al., 2023</xref>). Briefly, the dimer ratio of LRRK2 was determined on a Refeyn Two MP instrument (Refeyn). Prior to the experiment, a standard curve relating particle contrasts to molecular weight was established using a Native molecular weight standard (Invitrogen, 1:200 dilution in HEPES-based elution buffer: 50 mM HEPES [pH 8.0], 150 mM NaCl supplemented with 200 µM desthiobiotin). The LRRK2 protein was diluted to 2x of the final concentration (end concentration: 75 nM) in elution buffer. The optical setup was focused in 10 μl elution buffer before adding 10 µl of the adjusted protein sample. Depending on the obtained count numbers, acquisition times were chosen between 20 s to 1 min. The dimer ratio in each measurement was normalize according to the equation.
<disp-formula>
<alternatives><graphic xlink:href="549909v1_ueqn1.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
Three measurements were processed for each experimental condition, and data were analyzed by GraphPad Prism.</p>
</sec>
<sec id="s4h">
<title>Cell-based Rab assay</title>
<p>Cell-based LRRK2 activity assays were performed as previously described (<xref ref-type="bibr" rid="c45">Singh et al., 2022</xref>). Briefly, HEK293T cells were cultured in DMEM (supplemented with 10% Fetal Bovine Serum and 0.5% Pen/Strep). For the assay, the cells were seeded onto six-well plates and transfected at a confluency of 50-70% with SF-tagged LRRK2 variants using PEI-based lipofection. After 48 hours cells were lysed in lysis buffer [30 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NonidentP-40 substitute, complete protease inhibitor cocktail, PhosStop phosphatase inhibitors (Roche)]. Lysates were cleared by centrifugation at 10,000 x g and adjusted to a protein concentration of 1 µg/µl in 1x Laemmli Buffer. Samples were subsequently subjected to SDS PAGE and Western Blot analysis to determine LRRK2 pS935 and Rab10 T73 phosphorylation levels, as described below. Total LRRK2 and Rab10 levels were determined as a reference for normalization. For Western blot analysis, protein samples were separated by SDS–PAGE using NuPAGE 10% Bis-Tris gels (Invitrogen) and transferred onto PVDF membranes (Thermo Fisher). To allow simultaneous probing for LRRK2 on the one hand and Rab10 on the other hand, membranes were cut horizontally at the 140 kDa MW marker band. After blocking non-specific binding sites with 5% non-fat dry milk in TBST (1 h, RT) (25 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20), membranes were incubated overnight at 4°C with primary antibodies at dilutions specified below. Phospho-specific antibodies were diluted in TBST/ 5% BSA (Roth GmbH). Non-phospho-specific antibodies were diluted in TBST/ 5% non-fat dry milk powder (BioRad). Phospho-Rab10 levels were determined by the site-specific rabbit monoclonal antibody anti-pRAB10(pT73) (Abcam, ab230261) and LRRK2 pS935 was determined by the site-specific rabbit monoclonal antibody UDD2 (Abcam, ab133450), both at a dilution of 1:2,000. Total LRRK2 levels were determined by the in-house rat monoclonal antibody anti-pan-LRRK2 (clone 24D8; 1:10,000) (<xref ref-type="bibr" rid="c9">Carrion et al., 2017</xref>). Total Rab10 levels were determined by the rabbit monoclonal antibody anti-RAB10/ERP13424 (Abcam, ab181367) at a dilution of 1:5,000. For detection, goat anti-rat IgG or anti-rabbit IgG HRP-coupled secondary antibodies (Jackson ImmunoResearch) were used at a dilution of 1:15,000 in TBST/ 5% non-fat dry milk powder. Antibody–antigen complexes were visualized using the ECL plus chemiluminescence detection system (GE Healthcare) using the Stella imaging system (Raytest) for detection and quantification.</p>
</sec>
<sec id="s4i">
<title>Data analysis</title>
<p>GTP hydrolysis was determined from metadata extracted from the chromatograms. Based on these data, Michaelis-Menten fits were performed using GraFit5 (v5.0.13). Statistical significance of reported differences between the conditions was determined by ANOVA using Tukey post hoc test.</p>
</sec>
</sec>
</body>
<back>
<sec id="s5">
<title>Data availability</title>
<p>Raw data for Western blot quantifications are shown in the supplement.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>B.K.G., F.Y.H. and B.R. performed LRRK2 GTPase and kinase activity assays. G.G and X.Z. performed the mass photometry measurements. A.K. and C.J.G. designed the study. B.K.G., F.Y.H., A.K. and C.J.G. wrote the manuscript.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors are grateful to Felix von Zweydorf as well as to the working students for their technical assistance in cloning the different LRRK2 variants and maintaining the plasmids.</p>
</ack>
<sec id="s7">
<title>Funding</title>
<p>The work was supported by The Michael J. Fox Foundation for Parkinson’s Research (grant No: 8068.04 to C.J.G. and A.K.).</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Ahmadi Rastegar</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Dzamko</surname>, <given-names>N.</given-names></string-name> (<year>2020</year>). <article-title>Leucine Rich Repeat Kinase 2 and Innate Immunity</article-title>. <source>Front Neurosci</source> <volume>14</volume>, <fpage>193</fpage> doi: <pub-id pub-id-type="doi">10.3389/fnins.2020.00193</pub-id>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Ahmadian</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Hoffmann</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Goody</surname>, <given-names>R.S.</given-names></string-name>, and <string-name><surname>Wittinghofer</surname>, <given-names>A</given-names></string-name>. (<year>1997</year>). <article-title>Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy</article-title>. <source>Biochemistry</source> <volume>36</volume>, <fpage>4535</fpage>–<lpage>4541</lpage> doi: <pub-id pub-id-type="doi">10.1021/bi962556y</pub-id>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Beenstock</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mooshayef</surname>, <given-names>N.</given-names></string-name>, and <string-name><surname>Engelberg</surname>, <given-names>D</given-names></string-name>. (<year>2016</year>). <article-title>How Do Protein Kinases Take a Selfie (Autophosphorylate)?</article-title> <source>Trends Biochem Sci</source> <volume>41</volume>, <fpage>938</fpage>–<lpage>953</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.tibs.2016.08.006</pub-id>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Berger</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>K.A.</given-names></string-name>, and <string-name><surname>Lavoie</surname>, <given-names>M.J</given-names></string-name>. (<year>2010</year>). <article-title>Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation</article-title>. <source>Biochemistry</source> <volume>49</volume>, <fpage>5511</fpage>–<lpage>5523</lpage> doi: <pub-id pub-id-type="doi">10.1021/bi100157u</pub-id>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Biosa</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Trancikova</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Civiero</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Glauser</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Bubacco</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Greggio</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Moore</surname>, <given-names>D.J</given-names></string-name>. (<year>2013</year>). <article-title>GTPase activity regulates kinase activity and cellular phenotypes of Parkinson’s disease-associated LRRK2</article-title>. <source>Human molecular genetics</source> <volume>22</volume>, <fpage>1140</fpage>–<lpage>1156</lpage> doi: <pub-id pub-id-type="doi">10.1093/hmg/dds522</pub-id>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Birtwistle</surname>, <given-names>M.R.</given-names></string-name>, and <string-name><surname>Kolch</surname>, <given-names>W</given-names></string-name>. (<year>2011</year>). <article-title>Biology using engineering tools: the negative feedback amplifier</article-title>. <source>Cell Cycle</source> <volume>10</volume>, <fpage>2069</fpage>–<lpage>2076</lpage> doi: <pub-id pub-id-type="doi">10.4161/cc.10.13.16245</pub-id>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Bollag</surname>, <given-names>G.</given-names></string-name>, and <string-name><surname>McCormick</surname>, <given-names>F</given-names></string-name>. (<year>1995</year>). <article-title>Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays</article-title>. <source>Methods in enzymology</source> <volume>255</volume>, <fpage>161</fpage>–<lpage>170</lpage> doi: <pub-id pub-id-type="doi">10.1016/s0076-6879(95)55020-8</pub-id>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Bonet-Ponce</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Cookson</surname>, <given-names>M.R</given-names></string-name>. (<year>2019</year>). <article-title>The role of Rab GTPases in the pathobiology of Parkinson’ disease</article-title>. <source>Curr Opin Cell Biol</source> <volume>59</volume>, <fpage>73</fpage>–<lpage>80</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.ceb.2019.03.009</pub-id>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Carrion</surname>, <given-names>M.D.P.</given-names></string-name>, <string-name><surname>Marsicano</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Daniele</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Marte</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pischedda</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Di Cairano</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Piovesana</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kremmer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Onofri</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Perego</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Piccoli</surname>, <given-names>G.</given-names></string-name> (<year>2017</year>). <article-title>The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions</article-title>. <source>Sci Rep</source> <volume>7</volume>, <fpage>5377</fpage> doi: <pub-id pub-id-type="doi">10.1038/s41598-017-05760-9</pub-id>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Deniston</surname>, <given-names>C.K.</given-names></string-name>, <string-name><surname>Salogiannis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mathea</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Snead</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Lahiri</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Matyszewski</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Donosa</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Watanabe</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Bohning</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shiau</surname>, <given-names>A.K.</given-names></string-name>, <string-name><surname>Knapp</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Villa</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Reck-Peterson</surname>, <given-names>S.L.</given-names></string-name>, and <string-name><surname>Leschziner</surname>, <given-names>A.E</given-names></string-name>. (<year>2020</year>). <article-title>Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction</article-title>. <source>Nature</source> <volume>588</volume>, <fpage>344</fpage>–<lpage>349</lpage> doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2673-2</pub-id>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Deyaert</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Wauters</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Konijnenberg</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Leemans</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Terheyden</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Petrovic</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gallardo</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Nederveen-Schippers</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Athanasopoulos</surname>, <given-names>P.S.</given-names></string-name>, <string-name><surname>Pots</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Van Haastert</surname>, <given-names>P.J.M.</given-names></string-name>, <string-name><surname>Sobott</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Efremov</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Versees</surname>, <given-names>W.</given-names></string-name> (<year>2017</year>). <article-title>A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover</article-title>. <source>Nature communications</source> <volume>8</volume>, <fpage>1008</fpage> doi: <pub-id pub-id-type="doi">10.1038/s41467-017-01103-4</pub-id>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Ding</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Soule</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Overmeyer</surname>, <given-names>J.H.</given-names></string-name>, and <string-name><surname>Maltese</surname>, <given-names>W.A</given-names></string-name>. (<year>2003</year>). <article-title>Tyrosine phosphorylation of the Rab24 GTPase in cultured mammalian cells</article-title>. <source>Biochemical and biophysical research communications</source> <volume>312</volume>, <fpage>670</fpage>–<lpage>675</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2003.10.171</pub-id>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Erb</surname>, <given-names>M.L.</given-names></string-name>, and <string-name><surname>Moore</surname>, <given-names>D.J</given-names></string-name>. (<year>2020</year>). <article-title>LRRK2 and the Endolysosomal System in Parkinson’s Disease</article-title>. <source>J Parkinsons Dis</source> <volume>10</volume>, <fpage>1271</fpage>–<lpage>1291</lpage> doi: <pub-id pub-id-type="doi">10.3233/JPD-202138</pub-id>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Boldt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Schumacher</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Roepman</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Ueffing</surname>, <given-names>M</given-names></string-name>. (<year>2007</year>). <article-title>A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes</article-title>. <source>Proteomics</source> <volume>7</volume>, <fpage>4228</fpage>–<lpage>4234</lpage> doi: <pub-id pub-id-type="doi">10.1002/pmic.200700038</pub-id>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Boldt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Helm</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wiesent</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Sarioglu</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Ueffing</surname>, <given-names>M.</given-names></string-name> (<year>2010</year>). <article-title>Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2</article-title>. <source>Journal of proteome research</source> <volume>9</volume>, <fpage>1738</fpage>–<lpage>1745</lpage> doi: <pub-id pub-id-type="doi">10.1021/pr9008578</pub-id>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Kinkl</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Schumacher</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Braun</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>O’Neill</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Meitinger</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kolch</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Prokisch</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Ueffing</surname>, <given-names>M</given-names></string-name>. (<year>2006</year>). <article-title>The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity</article-title>. <source>Human molecular genetics</source> <volume>15</volume>, <fpage>223</fpage>–<lpage>232</lpage> doi: <pub-id pub-id-type="doi">10.1093/hmg/ddi439</pub-id>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, and <string-name><surname>Porras</surname>, <given-names>P</given-names></string-name>. (<year>2020</year>). <article-title>Guilt-by-Association - Functional Insights Gained From Studying the LRRK2 Interactome</article-title>. <source>Front Neurosci</source> <volume>14</volume>, <fpage>485</fpage> doi: <pub-id pub-id-type="doi">10.3389/fnins.2020.00485</pub-id>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Gomez</surname>, <given-names>R.C.</given-names></string-name>, <string-name><surname>Wawro</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lis</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Alessi</surname>, <given-names>D.R.</given-names></string-name>, and <string-name><surname>Pfeffer</surname>, <given-names>S.R</given-names></string-name>. (<year>2019</year>). <article-title>Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases</article-title>. <source>J Cell Biol</source> <volume>218</volume>, <fpage>4157</fpage>–<lpage>4170</lpage> doi: <pub-id pub-id-type="doi">10.1083/jcb.201902184</pub-id>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Gotthardt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Weyand</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Van Haastert</surname>, <given-names>P.J.</given-names></string-name>, and <string-name><surname>Wittinghofer</surname>, <given-names>A.</given-names></string-name> (<year>2008</year>). <article-title>Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase</article-title>. <source>The EMBO journal</source> <volume>27</volume>, <fpage>2239</fpage>–<lpage>2249</lpage> doi: <pub-id pub-id-type="doi">10.1038/emboj.2008.150</pub-id>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Greggio</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Taymans</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Zhen</surname>, <given-names>E.Y.</given-names></string-name>, <string-name><surname>Ryder</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Vancraenenbroeck</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Beilina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jaffe</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Baekelandt</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Merchant</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Cookson</surname>, <given-names>M.R</given-names></string-name>. (<year>2009</year>). <article-title>The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites</article-title>. <source>Biochemical and biophysical research communications</source> <volume>389</volume>, <fpage>449</fpage>–<lpage>454</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.08.163</pub-id>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Raimondi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gilsbach</surname>, <given-names>B.K.</given-names></string-name>, <string-name><surname>Gomez-Llorente</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Deyaert</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Renzi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Schaffner</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Jagtap</surname>, <given-names>P.K.</given-names></string-name>, <string-name><surname>Boldt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gotthardt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lorimer</surname>, <given-names>D.D.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Burgin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Janjic</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Sattler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Versees</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Ueffing</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ubarretxena-Belandia</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name> (<year>2016</year>). <article-title>Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>113</volume>, <fpage>E4357</fpage>–<lpage>4366</lpage> doi: <pub-id pub-id-type="doi">10.1073/pnas.1523708113</pub-id>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Saitta</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Miglionico</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Silbermann</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>F.Y.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Signorelli</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tych</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Fessas</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Raimondi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Gloeckner</surname>, <given-names>C.J</given-names></string-name>. (<year>2023</year>). <article-title>Biophysical analysis reveals autophosphorylation as an important regulator of LRRK2 dimerization</article-title>. <source>BioRxiv (preprint)</source>, ID:549911, manuscript ID: BIORXIV/2023/549911 (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org">https://www.biorxiv.org</ext-link>).</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Haugarvoll</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Rademakers</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kachergus</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Nuytemans</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ross</surname>, <given-names>O.A.</given-names></string-name>, <string-name><surname>Gibson</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>E.K.</given-names></string-name>, <string-name><surname>Gaig</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Tolosa</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Goldwurm</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Guidi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Riboldazzi</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Walter</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Benecke</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Berg</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Gasser</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Theuns</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Pals</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Cras</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>De Deyn</surname>, <given-names>P.P.</given-names></string-name>, <string-name><surname>Engelborghs</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pickut</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Uitti</surname>, <given-names>R.J.</given-names></string-name>, <etal>et al.</etal> (<year>2008</year>). <article-title>Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease</article-title>. <source>Neurology</source> <volume>70</volume>, <fpage>1456</fpage>–<lpage>1460</lpage> doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000304044.22253.03</pub-id>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Helton</surname>, <given-names>L.G.</given-names></string-name>, <string-name><surname>Soliman</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kentros</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Manschwetus</surname>, <given-names>J.T.</given-names></string-name>, <string-name><surname>Hall</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gilsbach</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>F.Y.</given-names></string-name>, <string-name><surname>Athanasopoulos</surname>, <given-names>P.S.</given-names></string-name>, <string-name><surname>Singh</surname>, <given-names>R.K.</given-names></string-name>, <string-name><surname>LeClair</surname>, <given-names>T.J.</given-names></string-name>, <string-name><surname>Versees</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Raimondi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Herberg</surname>, <given-names>F.W.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Rideout</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Kennedy</surname>, <given-names>E.J.</given-names></string-name> (<year>2021</year>). <article-title>Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides</article-title>. <source>ACS chemical biology</source> <volume>16</volume>, <fpage>2326</fpage>–<lpage>2338</lpage> doi: <pub-id pub-id-type="doi">10.1021/acschembio.1c00487</pub-id>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Ho</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Jang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Joe</surname>, <given-names>E.H.</given-names></string-name>, <string-name><surname>Son</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Seo</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Seol</surname>, <given-names>W</given-names></string-name>. (<year>2016</year>). <article-title>G2385R and I2020T Mutations Increase LRRK2 GTPase Activity</article-title>. <source>Biomed Res Int</source> <volume>2016</volume>, <fpage>7917128</fpage> doi: <pub-id pub-id-type="doi">10.1155/2016/7917128</pub-id>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Ito</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Okai</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Fujino</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ichijo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Katada</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Iwatsubo</surname>, <given-names>T</given-names></string-name>. (<year>2007</year>). <article-title>GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson’s disease</article-title>. <source>Biochemistry</source> <volume>46</volume>, <fpage>1380</fpage>–<lpage>1388</lpage> doi: <pub-id pub-id-type="doi">10.1021/bi061960m</pub-id>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Jaleel</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Nichols</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Deak</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Campbell</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Gillardon</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Knebel</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Alessi</surname>, <given-names>D.R</given-names></string-name>. (<year>2007</year>). <article-title>LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity</article-title>. <source>The Biochemical journal</source> <volume>405</volume>, <fpage>307</fpage>–<lpage>317</lpage> doi: <pub-id pub-id-type="doi">10.1042/BJ20070209</pub-id>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>James</surname>, <given-names>N.G.</given-names></string-name>, <string-name><surname>Digman</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Gratton</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Barylko</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ding</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Albanesi</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Goldberg</surname>, <given-names>M.S.</given-names></string-name>, and <string-name><surname>Jameson</surname>, <given-names>D.M.</given-names></string-name> (<year>2012</year>). <article-title>Number and brightness analysis of LRRK2 oligomerization in live cells</article-title>. <source>Biophys J</source> <volume>102</volume>, <fpage>L41</fpage>–<lpage>43</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.bpj.2012.04.046</pub-id>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Kalogeropulou</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Purlyte</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Tonelli</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Lange</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Wightman</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Prescott</surname>, <given-names>A.R.</given-names></string-name>, <string-name><surname>Padmanabhan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sammler</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Alessi</surname>, <given-names>D.R</given-names></string-name>. (<year>2022</year>). <article-title>Impact of 100 LRRK2 variants linked to Parkinson’s Disease on kinase activity and microtubule binding</article-title>. <source>The Biochemical journal</source> doi: <pub-id pub-id-type="doi">10.1042/BCJ20220161</pub-id>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Kolch</surname>, <given-names>W</given-names></string-name>. (<year>2000</year>). <article-title>Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</article-title>. <source>The Biochemical journal</source> <volume>351</volume> <issue>Pt 2</issue>, <fpage>289</fpage>–<lpage>305</lpage> doi:</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Leupold</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Goody</surname>, <given-names>R.S.</given-names></string-name>, and <string-name><surname>Wittinghofer</surname>, <given-names>A</given-names></string-name>. (<year>1983</year>). <article-title>Stereochemistry of the elongation factor Tu X GTP complex</article-title>. <source>Eur J Biochem</source> <volume>135</volume>, <fpage>237</fpage>–<lpage>241</lpage> doi: <pub-id pub-id-type="doi">10.1111/j.1432-1033.1983.tb07643.x</pub-id>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Lewis</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Greggio</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Beilina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Jain</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Baker</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Cookson</surname>, <given-names>M.R</given-names></string-name>. (<year>2007</year>). <article-title>The R1441C mutation of LRRK2 disrupts GTP hydrolysis</article-title>. <source>Biochemical and biophysical research communications</source> <volume>357</volume>, <fpage>668</fpage>–<lpage>671</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.04.006</pub-id>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dobson</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Glicksman</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>Stein</surname>, <given-names>R.L</given-names></string-name>. (<year>2010</year>). <article-title>Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities</article-title>. <source>Biochemistry</source> <volume>49</volume>, <fpage>2008</fpage>–<lpage>2017</lpage> doi: <pub-id pub-id-type="doi">10.1021/bi901851y</pub-id>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Mobley</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>DeLucas</surname>, <given-names>L.J.</given-names></string-name>, <string-name><surname>Kahn</surname>, <given-names>R.A.</given-names></string-name>, and <string-name><surname>West</surname>, <given-names>A.B</given-names></string-name>. (<year>2016</year>). <article-title>LRRK2 autophosphorylation enhances its GTPase activity</article-title>. <source>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</source> <volume>30</volume>, <fpage>336</fpage>–<lpage>347</lpage> doi: <pub-id pub-id-type="doi">10.1096/fj.15-277095</pub-id>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>West</surname>, <given-names>A.B</given-names></string-name>. (<year>2017</year>). <article-title>The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro</article-title>. <source>Biochim Biophys Acta Proteins Proteom</source> <volume>1865</volume>, <fpage>274</fpage>–<lpage>280</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.bbapap.2016.12.001</pub-id>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Marin</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>van Egmond</surname>, <given-names>W.N.</given-names></string-name>, and <string-name><surname>van Haastert</surname>, <given-names>P.J.</given-names></string-name> (<year>2008</year>). <article-title>The Roco protein family: a functional perspective</article-title>. <source>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</source> <volume>22</volume>, <fpage>3103</fpage>–<lpage>3110</lpage> doi: <pub-id pub-id-type="doi">10.1096/fj.08-111310</pub-id>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Menges</surname>, <given-names>C.W.</given-names></string-name>, and <string-name><surname>McCance</surname>, <given-names>D.J</given-names></string-name>. (<year>2008</year>). <article-title>Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor</article-title>. <source>Oncogene</source> <volume>27</volume>, <fpage>2934</fpage>–<lpage>2940</lpage> doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1210957</pub-id>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Mills</surname>, <given-names>R.D.</given-names></string-name>, <string-name><surname>Mulhern</surname>, <given-names>T.D.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>H.C.</given-names></string-name>, and <string-name><surname>Culvenor</surname>, <given-names>J.G</given-names></string-name>. (<year>2012</year>). <article-title>Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson’s disease mutations</article-title>. <source>Biochemical Society transactions</source> <volume>40</volume>, <fpage>1086</fpage>–<lpage>1089</lpage> doi: <pub-id pub-id-type="doi">10.1042/BST20120088</pub-id>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Mishra</surname>, <given-names>A.K.</given-names></string-name>, <string-name><surname>Del Campo</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>R.E.</given-names></string-name>, <string-name><surname>Roy</surname>, <given-names>C.R.</given-names></string-name>, and <string-name><surname>Lambright</surname>, <given-names>D.G</given-names></string-name>. (<year>2013</year>). <article-title>The Legionella pneumophila GTPase activating protein LepB accelerates Rab1 deactivation by a non-canonical hydrolytic mechanism</article-title>. <source>The Journal of biological chemistry</source> <volume>288</volume>, <fpage>24000</fpage>–<lpage>24011</lpage> doi: <pub-id pub-id-type="doi">10.1074/jbc.M113.470625</pub-id>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Myasnikov</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hixson</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Pitre</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Peng</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Sun</surname>, <given-names>J</given-names></string-name>. (<year>2021</year>). <article-title>Structural analysis of the full-length human LRRK2</article-title>. <source>Cell</source> <volume>184</volume>, <fpage>3519</fpage>–<lpage>3527</lpage> e3510 doi: <pub-id pub-id-type="doi">10.1016/j.cell.2021.05.004</pub-id>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Paisan-Ruiz</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jain</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Evans</surname>, <given-names>E.W.</given-names></string-name>, <string-name><surname>Gilks</surname>, <given-names>W.P.</given-names></string-name>, <string-name><surname>Simon</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>van der Brug</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lopez de Munain</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Aparicio</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gil</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Khan</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Martinez</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Nicholl</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Marti Carrera</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Pena</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>de Silva</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lees</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Marti-Masso</surname>, <given-names>J.F.</given-names></string-name>, <string-name><surname>Perez-Tur</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wood</surname>, <given-names>N.W.</given-names></string-name>, and <string-name><surname>Singleton</surname>, <given-names>A.B.</given-names></string-name> (<year>2004</year>). <article-title>Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease</article-title>. <source>Neuron</source> <volume>44</volume>, <fpage>595</fpage>–<lpage>600</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2004.10.023</pub-id>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Pathak</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Alexander</surname>, <given-names>K.K.</given-names></string-name>, <string-name><surname>Helton</surname>, <given-names>L.G.</given-names></string-name>, <string-name><surname>Kentros</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>LeClair</surname>, <given-names>T.J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>F.Y.</given-names></string-name>, <string-name><surname>Moore</surname>, <given-names>T.T.</given-names></string-name>, <string-name><surname>Hall</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rideout</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Kennedy</surname>, <given-names>E.J</given-names></string-name>. (<year>2023</year>). <article-title>Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization</article-title>. <source>ACS Chem Neurosci</source> <volume>14</volume>, <fpage>1971</fpage>–<lpage>1980</lpage> doi: <pub-id pub-id-type="doi">10.1021/acschemneuro.3c00259</pub-id>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Riggs</surname>, <given-names>P</given-names></string-name>. (<year>2001</year>). <article-title>Expression and purification of maltose-binding protein fusions</article-title>. <source>Curr Protoc Mol Biol Chapter</source> <volume>16</volume>, Unit16 16 doi: <pub-id pub-id-type="doi">10.1002/0471142727.mb1606s28</pub-id>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Simon-Sanchez</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Schulte</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bras</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Sharma</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gibbs</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Berg</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Paisan-Ruiz</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Lichtner</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Scholz</surname>, <given-names>S.W.</given-names></string-name>, <string-name><surname>Hernandez</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Kruger</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Federoff</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Goate</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Perlmutter</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bonin</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Nalls</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Illig</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Gieger</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Houlden</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Steffens</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Okun</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Racette</surname>, <given-names>B.A.</given-names></string-name>, <string-name><surname>Cookson</surname>, <given-names>M.R.</given-names></string-name>, <etal>et al.</etal> (<year>2009</year>). <article-title>Genome-wide association study reveals genetic risk underlying Parkinson’s disease</article-title>. <source>Nat Genet</source> <volume>41</volume>, <fpage>1308</fpage>–<lpage>1312</lpage> doi: <pub-id pub-id-type="doi">10.1038/ng.487</pub-id>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Singh</surname>, <given-names>R.K.</given-names></string-name>, <string-name><surname>Soliman</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Stormer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>von Zweydorf</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Dal Maso</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Oun</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Van Rillaer</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Chatterjee</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>David</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Pardon</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Schwartz</surname>, <given-names>T.U.</given-names></string-name>, <string-name><surname>Knapp</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kennedy</surname>, <given-names>E.J.</given-names></string-name>, <string-name><surname>Steyaert</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Herberg</surname>, <given-names>F.W.</given-names></string-name>, <string-name><surname>Kortholt</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, and <string-name><surname>Versees</surname>, <given-names>W.</given-names></string-name> (<year>2022</year>). <article-title>Nanobodies as allosteric modulators of Parkinson’s disease-associated LRRK2</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>119</volume> doi: <pub-id pub-id-type="doi">10.1073/pnas.2112712119</pub-id>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Steger</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tonelli</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ito</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Davies</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Trost</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Vetter</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wachter</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lorentzen</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Duddy</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Baptista</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Fiske</surname>, <given-names>B.K.</given-names></string-name>, <string-name><surname>Fell</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Morrow</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Reith</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Alessi</surname>, <given-names>D.R.</given-names></string-name>, and <string-name><surname>Mann</surname>, <given-names>M</given-names></string-name>. (<year>2016</year>). <article-title>Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases</article-title>. <source>Elife</source> <volume>5</volume> doi: <pub-id pub-id-type="doi">10.7554/eLife.12813</pub-id>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Stormer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Weng</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bertinetti</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Kaila Sharma</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Herberg</surname>, <given-names>F.W.</given-names></string-name>, and <string-name><surname>Taylor</surname>, <given-names>S</given-names></string-name>. (<year>2023</year>). <article-title>Capturing the domain crosstalk in full length LRRK2 and LRRK2RCKW</article-title>. <source>The Biochemical journal</source> doi: <pub-id pub-id-type="doi">10.1042/BCJ20230126</pub-id>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Taylor</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Kaila-Sharma</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Weng</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Aoto</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Knapp</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mathea</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Herberg</surname>, <given-names>F.W</given-names></string-name>. (<year>2020</year>). <article-title>Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery</article-title>. <source>Frontiers in molecular neuroscience</source> <volume>13</volume>, <fpage>538219</fpage> doi: <pub-id pub-id-type="doi">10.3389/fnmol.2020.538219</pub-id>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>Taymans</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Fell</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Greenamyre</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hirst</surname>, <given-names>W.D.</given-names></string-name>, <string-name><surname>Mamais</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Padmanabhan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Peter</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Rideout</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Thaler</surname>, <given-names>A</given-names></string-name>. (<year>2023</year>). <article-title>Perspective on the current state of the LRRK2 field</article-title>. <source>NPJ Parkinsons Dis</source> <volume>9</volume>, <fpage>104</fpage> doi: <pub-id pub-id-type="doi">10.1038/s41531-023-00544-7</pub-id>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><string-name><surname>Taymans</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Vancraenenbroeck</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ollikainen</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Beilina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lobbestael</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>De Maeyer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Baekelandt</surname>, <given-names>V.</given-names></string-name>, and <string-name><surname>Cookson</surname>, <given-names>M.R.</given-names></string-name> (<year>2011</year>). <article-title>LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding</article-title>. <source>PloS one</source> <volume>6</volume>, <fpage>e23207</fpage> doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0023207</pub-id>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Traut</surname>, <given-names>T.W</given-names></string-name>. (<year>1994</year>). <article-title>Physiological concentrations of purines and pyrimidines</article-title>. <source>Mol Cell Biochem</source> <volume>140</volume>, <fpage>1</fpage>–<lpage>22</lpage> doi: <pub-id pub-id-type="doi">10.1007/BF00928361</pub-id>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><string-name><surname>Wauters</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Terheyden</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gilsbach</surname>, <given-names>B.K.</given-names></string-name>, <string-name><surname>Leemans</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Athanasopoulos</surname>, <given-names>P.S.</given-names></string-name>, <string-name><surname>Guaitoli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wittinghofer</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gloeckner</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Versees</surname>, <given-names>W.</given-names></string-name>, and <string-name><surname>Kortholt</surname>, <given-names>A</given-names></string-name>. (<year>2018</year>). <article-title>Biochemical and kinetic properties of the complex Roco G-protein cycle</article-title>. <source>Biol Chem</source> <volume>399</volume>, <fpage>1447</fpage>–<lpage>1456</lpage> doi: <pub-id pub-id-type="doi">10.1515/hsz-2018-0227</pub-id>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><string-name><surname>Webber</surname>, <given-names>P.J.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Sen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Renfrow</surname>, <given-names>M.B.</given-names></string-name>, <string-name><surname>Mobley</surname>, <given-names>J.A.</given-names></string-name>, and <string-name><surname>West</surname>, <given-names>A.B</given-names></string-name>. (<year>2011</year>). <article-title>Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities</article-title>. <source>Journal of molecular biology</source> <volume>412</volume>, <fpage>94</fpage>–<lpage>110</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.jmb.2011.07.033</pub-id>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><string-name><surname>Wojewska</surname>, <given-names>D.N.</given-names></string-name>, and <string-name><surname>Kortholt</surname>, <given-names>A</given-names></string-name>. (<year>2021</year>). <article-title>LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease</article-title>. <source>Biomolecules</source> <volume>11</volume> doi: <pub-id pub-id-type="doi">10.3390/biom11081101</pub-id>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><string-name><surname>Wu</surname>, <given-names>C.-X.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hoang</surname>, <given-names>N.C.</given-names></string-name>, <string-name><surname>Engel</surname>, <given-names>V.A.</given-names></string-name>, <string-name><surname>Wan</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Oh</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sanishvili</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Takagi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Federici</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Nichols</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Beilina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Reed</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Cookson</surname>, <given-names>M.R.</given-names></string-name>, and <string-name><surname>Hoang</surname>, <given-names>Q.Q</given-names></string-name>. (<year>2019</year>). <article-title>A revised 1.6 Å structure of the GTPase domain of the Parkinson’s disease-associated protein LRRK2 provides insights into mechanisms</article-title>. <source>BioRxiv</source> doi: <pub-id pub-id-type="doi">10.1101/676627</pub-id>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><string-name><surname>Wu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Yin</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Ji</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tang</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Dong</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Mao</surname>, <given-names>Y</given-names></string-name>. (<year>2006</year>). <article-title>Human RAB24, interestingly and predominantly distributed in the nuclei of COS-7 cells, is colocalized with cyclophilin A and GABARAP</article-title>. <source>Int J Mol Med</source> <volume>17</volume>, <fpage>749</fpage>–<lpage>754</lpage> doi:</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><string-name><surname>Zimprich</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Biskup</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Leitner</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lichtner</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Farrer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lincoln</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kachergus</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hulihan</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Uitti</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Calne</surname>, <given-names>D.B.</given-names></string-name>, <string-name><surname>Stoessl</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Pfeiffer</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Patenge</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Carbajal</surname>, <given-names>I.C.</given-names></string-name>, <string-name><surname>Vieregge</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Asmus</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Muller-Myhsok</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Dickson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Meitinger</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Strom</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Wszolek</surname>, <given-names>Z.K.</given-names></string-name>, and <string-name><surname>Gasser</surname>, <given-names>T</given-names></string-name>. (<year>2004</year>). <article-title>Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</article-title>. <source>Neuron</source> <volume>44</volume>, <fpage>601</fpage>–<lpage>607</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2004.11.005</pub-id>.</mixed-citation></ref>
</ref-list>
<sec id="d1e4548">
<title>Supplemental Figures and Tables</title>
<sec>
<title>Tables</title>
<table-wrap id="tbls1" orientation="portrait" position="float">
<label>Supplemental-Table 1:</label>
<caption><title>MBP-RocCOR Michaelis-Menten kinetics as measured by charcoal based GTPase assay.</title></caption>
<graphic xlink:href="549909v1_tbls1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls2" orientation="portrait" position="float">
<label>Supplemental-Table 2:</label>
<caption><title>GTPase activity (k<sub>obs</sub>) as measured by charcoal based GTPase assay.</title></caption>
<graphic xlink:href="549909v1_tbls2.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls3" orientation="portrait" position="float">
<label>Supplemental-Table 3:</label>
<caption><title>Cell-based phospho-Rab assays. Quantification of Western Blots</title></caption>
<graphic xlink:href="549909v1_tbls3.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec>
<title>Figures</title>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 1:</label>
<caption><p>Michaelis-Menten kinetics for MLi-2 treated LRRK2 wt.</p></caption>
<graphic xlink:href="549909v1_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 2:</label>
<caption><p>Initial Phosphosite-screen (alanine screen). Michaelis-Menten parameters were determined in dependence of ATP pre-incubation. (A) K<sub>M</sub> values. (B) k<sub>cat</sub> values. The number of replicates is indicated.</p></caption>
<graphic xlink:href="549909v1_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 3:</label>
<caption><p>Raw data for the <italic>In vitro</italic> LRRKtide HPLC Assay (determination of k<sub>obs</sub> values). (A) LRRK2 G2019S, (B) LRRK2 wt, (C) LRRK2 T1343A, (D) kinase-dead (KD) LRRK2 K1906M.</p></caption>
<graphic xlink:href="549909v1_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 4:</label>
<caption><p>Cell-based phosphor-Rab assays, blot raw images used for quantification. (A-C) biological replicates.</p></caption>
<graphic xlink:href="549909v1_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91083.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dötsch</surname>
<given-names>Volker</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Goethe University Frankfurt</institution>
</institution-wrap>
<city>Frankfurt am Main</city>
<country>Germany</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>valuable</bold> manuscript reports on the relationship between GTP hydrolysis parameters and kinase activity of LRRK2, which is associated with Parkinson's disease. The authors provide a detailed accounting of the catalytic efficiency of the ROC GTPase domain of pathogenic variants of LRRK2, in comparison with the wild-type enzyme. The authors propose that phosphorylation of T1343 inhibits kinase activity and influences monomer-dimer transitions, but the experimental evidence is currently <bold>incomplete</bold>.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91083.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
This study presents careful biochemical experiments to understand the relationship between LRRK2 GTP hydrolysis parameters and LRRK2 kinase activity. The authors report that incubation of LRRK2 with ATP increases the KM for GTP and decreases the kcat. From this, they suppose an autophosphorylation process is responsible for enzyme inhibition. LRRK2 T1343A showed no change, consistent with it needing to be phosphorylated to explain the changes in G-domain properties. The authors propose that phosphorylation of T1343 inhibits kinase activity and influences monomer-dimer transitions.</p>
<p>Strengths:</p>
<p>
The strengths of the work are the very careful biochemical analyses and the interesting result for wild-type LRRK2.</p>
<p>Weaknesses:</p>
<p>
A major unexplained weakness is why the mutant T1343A starts out with so much lower activity--it should be the same as wild-type, non-phosphorylated protein. Also, if a monomer-dimer transition is involved, it should be either all or nothing. Other approaches would add confidence to the findings.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91083.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This study addresses the catalytic activity of a Ras-like ROC GTPase domain of LRRK2 kinase, a Ser/Thr kinase linked to Parkinson's disease (PD). The enzyme is associated with gain-of-function variants that hyper-phosphorylate substrate Rab GTPases. However, the link between the regulatory ROC domain and activation of the kinase domain is not well understood.</p>
<p>It is within this context that the authors detail the kinetics of the ROC GTPase domain of pathogenic variants of LRRK2, in comparison to the WT enzyme. Their data suggest that LRRK2 kinase activity negatively regulates the ROC GTPase activity and that PD variants of LRRK2 have differential effects on the Km and catalytic efficiency of GTP hydrolysis.</p>
<p>Based on mutagenesis, kinetics, and biophysical experiments, the authors suggest a model in which autophosphorylation shifts the equilibrium toward monomeric LRRK2 (locked GTP state of ROC). The authors further conclude that T1343 is a crucial regulatory site, located in the P-loop of the ROC domain, which is necessary for the negative feedback mechanism. Unfortunately, the data do not support this hypothesis, and further experiments are required to confirm this model for the regulation of LRRK2 activity.</p>
<p>Specific comments are below:</p>
<p>- Although a couple of papers are cited, the rationale for focusing on the T1343 site is not evident to readers. It should be clarified that this locus, and perhaps other similar loci in the wider ROCO family, are likely important for direct interactions with the GTP molecule.</p>
<p>- Similar to the above, readers are kept in the dark about auto-phosphorylation and its effects on the monomer/dimer equilibrium. This is a critical aspect of this manuscript and a major conceptual finding that the authors are making from their data. However, the idea that auto-phosphorylation is (likely) to shift the monomer/dimer equilibrium toward monomer, thereby inactivating the enzyme, is not presented until page 6, AFTER describing much of their kinetics data. This is very confusing to readers, as it is difficult to understand the meaning of the data without a conceptual framework. If the model for the LRRK2 function is that dimerization is necessary for the phosphorylation of substrates, then this idea should be presented early in the introduction, and perhaps also in the abstract. If there are caveats, then they should be discussed before data are presented. A clear literature trail and the current accepted (or consensus) mechanism for LRRK2 activity is necessary to better understand the context for these data.</p>
<p>- Following on the above concepts, I find it interesting that the authors mention monomeric cyotosolic states, and kinase-active oligomers (dimers??), with citations. Again here, it would be useful to be more precise. Are dimers (oligomers?) only formed at the membrane? That would suggest mechanisms involving lipid or membrane-attached protein interactions. Also, what do the authors mean by oligomers? Are there more than dimers found localized to the membrane?</p>
<p>- Fig 5 is a key part of their findings, regarding the auto-phosphorylation induced monomer formation of LRRK2. From these two bar graphs, the authors state unequivocally that the 'monomer/dimer equilibrium is abolished', and therefore, that the underlying mechanism might be increased monomerization (through maintenance of a GTP-locked state). My view is that the authors should temper these conclusions with caveats. One is that there are still plenty of dimers in the auto-phosphorylated WT, and also in the T1343A mutant. Why is that the case? Can the authors explain why only perhaps a 10% shift is sufficient? Secondly, the T1343A mutant appears to have fewer overall dimers to begin with, so it appears to readers that 'abolition' is mainly due to different levels prior to ATP treatment at 30 deg. I feel these various issues need to be clarified in a revised manuscript, with additional supporting data. Finally, on a minor note, I presume that there are no statistically significant differences between the two sets of bar graphs on the right panel. It would be wise to place 'n.s.' above the graphs for readers, and in the figure legend, so readers are not confused.</p>
<p>- Figure 6B, Westerns of phosphorylation, the lanes are not identified and it is unclear what these data mean.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91083.1.sa3</article-id>
<title-group>
<article-title>Author Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gilsbach</surname>
<given-names>Bernd K.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1323-5541</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Ho</surname>
<given-names>Franz Y.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3663-2889</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Riebenbauer</surname>
<given-names>Benjamin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiaojuan</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0005-1579-6851</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Guaitoli</surname>
<given-names>Giambattista</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4442-3841</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Kortholt</surname>
<given-names>Arjan</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8174-6397</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Gloeckner</surname>
<given-names>Christian Johannes</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6494-6944</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p>Summary:</p>
<p>This study presents careful biochemical experiments to understand the relationship between LRRK2 GTP hydrolysis parameters and LRRK2 kinase activity. The authors report that incubation of LRRK2 with ATP increases the KM for GTP and decreases the kcat. From this, they suppose an
autophosphorylation process is responsible for enzyme inhibition. LRRK2 T1343A showed no change, consistent with it needing to be phosphorylated to explain the changes in G-domain properties. The authors propose that phosphorylation of T1343 inhibits kinase activity and influences monomer-dimer transitions.</p>
<p>Strengths:
The strengths of the work are the very careful biochemical analyses and the interesting result for wild-type LRRK2.</p>
<p>Weaknesses:</p>
<p>A major unexplained weakness is why the mutant T1343A starts out with so much lower activity--it should be the same as wild-type, non-phosphorylated protein. Also, if a monomer-dimer transition is involved, it should be either all or nothing. Other approaches would add confidence to the findings.</p>
</disp-quote>
<p>We thank the reviewer for these suggestions. We are aware that the T1343A has generally a lower activity compared to the wild type. Therefore, we would like to emphasize that this mutant is the only one not showing an increase in Km values after ATP treatment. Other mutants, also having lower kcat values like T1503A, still show this characteristic change in Km. Our favored explanation for the lower kcat of T1343A is that this mutation lays within a critical region, the so-called ploop, of the Roc domain and is very likely structurally not neutral. Concerning the dimer-monomer transition, we are convinced that there is more than one factor involved in this equilibrium. Most likely, including, but not limited to other LRRK2 domains (e.g. the WD40 domain), binding of co-factors (e.g. Rab29/Rab32 or 14-3-3) and membrane binding. Consistently, also n with stapled peptides targeting the Roc or Cor domains we were not able to shift the equilibrium completely to the monomer (Helton et al., ACS Chem Biol. 2021, 16:2326-2338; Pathak et al. ACS Chem Neurosci. 2023, 14(11):1971-1980) We will address these points in a revised version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>This study addresses the catalytic activity of a Ras-like ROC GTPase domain of LRRK2 kinase, a Ser/Thr kinase linked to Parkinson's disease (PD). The enzyme is associated with gain-of-function variants that hyper-phosphorylate substrate Rab GTPases. However, the link between the regulatory ROC domain and activation of the kinase domain is not well understood. It is within this context that the authors detail the kinetics of the ROC GTPase domain of pathogenic variants of LRRK2, in comparison to the WT enzyme. Their data suggest that LRRK2 kinase activity negatively regulates the ROC GTPase activity and that PD variants of LRRK2 have differential effects on the Km and catalytic efficiency of GTP hydrolysis. Based on mutagenesis, kinetics, and biophysical experiments, the authors suggest a model in which autophosphorylation shifts the equilibrium toward monomeric LRRK2 (locked GTP state of ROC). The authors further conclude that T1343 is a crucial regulatory site, located in the P-loop of the ROC domain, which is necessary for the negative feedback mechanism. Unfortunately, the data do not support this hypothesis, and further experiments are required to confirm this model for the regulation of LRRK2 activity.</p>
<p>Specific comments are below:</p>
<list list-type="bullet">
<list-item><p>Although a couple of papers are cited, the rationale for focusing on the T1343 site is not evident to readers. It should be clarified that this locus, and perhaps other similar loci in the wider ROCO family, are likely important for direct interactions with the GTP molecule.</p>
</list-item></list>
</disp-quote>
<p>To clarify this point: We, have not only have focused on this specific locus, but instead systematically mutated all known auto-phosphorylation sites with the RocCOR domain (see. supplemental information). Furthermore, it has been shown that this site, at least in the RCKW (Roc to WD40) construct, is quantitatively phosphorylated (Deniston et al., Nature 2020, 588:344-349). We are aware that the T1343 residue is located within the p-loop and that this can impact nucleotide binding capacities (see response to reviewer 1). We will clarify and address these points in a revised version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<list list-type="bullet">
<list-item><p>Similar to the above, readers are kept in the dark about auto-phosphorylation and its effects on the monomer/dimer equilibrium. This is a critical aspect of this manuscript and a major conceptual finding that the authors are making from their data. However, the idea that auto-phosphorylation is (likely) to shift the monomer/dimer equilibrium toward monomer, thereby inactivating the enzyme, is not presented until page 6, AFTER describing much of their kinetics data. This is very confusing to readers, as it is difficult to understand the meaning of the data without a conceptual framework. If the model for the LRRK2 function is that dimerization is necessary for the phosphorylation of substrates, then this idea should be presented early in the introduction, and perhaps also in the abstract. If there are caveats, then they should be discussed before data are presented. A clear literature trail and the current accepted (or consensus) mechanism for LRRK2 activity is necessary to better understand the context for these data.</p>
</list-item></list>
</disp-quote>
<p>We agree on the reviewer’s opinion. We will address this point in a revised version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<list list-type="bullet">
<list-item><p>Following on the above concepts, I find it interesting that the authors mention monomeric cytosolic states, and kinase-active oligomers (dimers??), with citations. Again here, it would be useful to be more precise. Are dimers (oligomers?) only formed at the membrane? That would suggest mechanisms involving lipid or membrane-attached protein interactions. Also, what do the authors mean by oligomers? Are there more than dimers found localized to the membrane?</p>
</list-item></list>
</disp-quote>
<p>There are multiple studies that have shown that LRRK2 is mainly monomeric in the cytosol while it forms mainly dimeric or higher oligomeric states at membrane (James et al., Biophys. J. 2012, 102, L41–L43; Berger et al., Biochemistry, 2010, 49, 5511–5523). However, we agree with the reviewer that it remains to be determined if the dimeric form is the most active state at the membrane, or a higher oligomeric state. Especially since a recent study shows that LRRK2 can form active tetramers only when bound to Rab29 (Zhu et al., bioRxiv, 2022, DOI: 10.1101/2022.04.26.489605). We will clarify and address these points in the introduction of a revised version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<list list-type="bullet">
<list-item><p>Fig 5 is a key part of their findings, regarding the auto-phosphorylation induced monomer formation of LRRK2. From these two bar graphs, the authors state unequivocally that the 'monomer/dimer equilibrium is abolished', and therefore, that the underlying mechanism might be increased monomerization (through maintenance of a GTP-locked state). My view is that the authors should temper these conclusions with caveats. One is that there are still plenty of dimers in the auto-phosphorylated WT, and also in the T1343A mutant. Why is that the case? Can the authors explain why only perhaps a 10% shift is sufficient? Secondly, the T1343A mutant appears to have fewer overall dimers to begin with, so it appears to readers that 'abolition' is mainly due to different levels prior to ATP treatment at 30 deg. I feel these various issues need to be clarified in a revised manuscript, with additional supporting data. Finally, on a minor note, I presume that there are no statistically significant differences between the two sets of bar graphs on the right panel. It would be wise to place 'n.s.' above the graphs for readers, and in the figure legend, so readers are not confused.</p>
</list-item></list>
</disp-quote>
<p>Starting with the monomer-dimer equilibrium we are convinced that there is more than the phosphorylation of T1343 (see response to reviewer 1). Therefore a 10% shift in our assay most likely underestimate the effect seen in cells.</p>
<p>Consistently, the T1343A mutants show a similar increase in Rab10 phosphorylation assay as the G2019S mutant. This thus shows that the identified feedback mechanism plays an important role in a cellular context. We will explain this in more detail in a revised version of the manuscript. Concerning the bar diagram, we will add the “n.s.” indication in a future version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<list list-type="bullet">
<list-item><p>Figure 6B, Westerns of phosphorylation, the lanes are not identified and it is unclear what these data mean.</p>
</list-item></list>
</disp-quote>
<p>We apologize for this mistake and will add the correct labeling in a revised version of the manuscript.</p>
</body>
</sub-article>
</article>